Guido Bonati is the new Chief Technology Officer and Head of Research & Development at FISBA AG
He structures the services required of R&D with the resources, ideas and potential and deploys efficient teams to successfully handle customer projects.
Guido Bonati was awarded a PhD in mechanical engineering, specializing in laser technology and design, at RWTH Aachen University in North Rhine-Westphalia, Germany.
He has worked in management positions all over the world for various companies in the optical industry, including in the fields of laser technology and optics, for over 25 years.
In his new position at FISBA, he can rely on his experience and in-depth knowledge in the development, production and business development fields.
Guido Bonati succeeds Christian Zellweger, who has taken up a new challenge within the company as its COO.
About FISBA Since 1957, FISBA has been supplying customers in the photonics sector with the industry’s largest range of design and manufacturing capacities for optical components and systems. Highly specialized teams satisfy the complex requirements of customers from the strictly regulated life sciences, defense and aerospace, industrial manufacturing and material processing fields and help world-leading brands fulfill their market potential. FISBA's services, which are centered on its customers, range from concept design through support in device development to engineering, supply-chain optimization and assembly. Our specially equipped branch offices that meet the strict market requirements while protecting our customers' intellectual property are ready to fulfill this purpose. FISBA runs operations at sites in Switzerland, Germany, USA and China.
Head of Corporate Marketing Communication
All latest news from the category: Corporate News
Scientists identify novel molecular biomarkers in cells
Studying a deadly type of breast cancer called triple negative, Johns Hopkins Medicine scientists say they have identified key molecular differences between cancer cells that cling to an initial tumor…